Sylentis was founded in 2006 as a spin-off within the Zeltia Group, with the mission of building a solid and sustainable business and becoming a therapeutic platform based on RNA interference.Sylentis’ pipeline is directed towards indications with an elevated market potential, including ocular pathologies, inflammatory diseases and central nervous system diseases.
********************
ECCO : EUROPEAN CROHN,S AND COLITIS ORGANISATION .